Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 2,103 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Autism Spectrum Disorder
Interventions: IGF-1, Placebo/saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 5 Years to 12 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Cervical Dystonia
Interventions: incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hot Flashes, Hot Flushes, Vasomotor Symptoms
Interventions: Stellate Ganglion Block Injection with Bupivicaine, Saline injection; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years to 70 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Bariatric Surgery Candidate, Pain, Postoperative
Interventions: Exparel 266 MG Per 20 ML Injection, Bupivacaine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 231 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Fresno, California

Conditions: Cystectomy
Interventions: epidural bupivacaine 0.05%, Liposomal bupivacaine, bupivacaine 0.125%, bupivacaine 0.5%, /hydromorphone 0.05mg/ml, injectable saline; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Opioid Overdose, Opioid Use Disorder
Interventions: CSX-1004, Placebo; Biological
Lead sponsor: Cessation Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Acute Intermittent Porphyria
Interventions: givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Birmingham, Alabama • San Francisco, California • New York, New York + 1 more

Conditions: Breast Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 11
States / cities: Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more

Conditions: Leukemia
Interventions: Clofarabine; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Peripheral Artery Disease, Critical Limb Ischemia
Interventions: Temsirolimus, Saline placebo; Drug
Lead sponsor: Mercator MedSystems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 2
States / cities: Houma, Louisiana • Dallas, Texas

Conditions: Pemphigus Vulgaris
Interventions: Ofatumumab, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Atlanta, Georgia • Ann Arbor, Michigan + 4 more

Conditions: Chronic Testicular Pain
Interventions: Botox Injection, Normal saline injection; Drug · Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Male only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Type 2 Diabetes
Interventions: Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Chronic Migraine, Headache
Interventions: Preserved saline in reconstitution of Botox; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 79 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Atrial Fibrillation
Interventions: Botulinum Toxin Type A, Placebo; Drug
Lead sponsor: Joseph Mathew, M.D.; Other
Eligibility: 50 Years to 90 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hip Pain Chronic, Hip Impingement Syndrome, Hip Injuries, Blood Loss, Femoro Acetabular Impingement
Interventions: Tranexamic acid, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Kidney Diseases
Interventions: Visipaque, Placebos; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 17
States / cities: Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 14 more

Conditions: Abdominoplasty
Interventions: Botulinum Neurotoxin Serotype E, Placebo; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 23 Years to 55 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 2
States / cities: Pasadena, California

Conditions: Breast Cancer
Interventions: TMEM-MRI, FNA; Device · Procedure
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Multiple Sclerosis
Interventions: Methylprednisolone, ACTH, IV placebo, IM placebo; Drug · Other
Lead sponsor: Neurologique Foundation, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Ponte Vedra, Florida

Conditions: Myofascial Pain Syndrome
Interventions: Normal Saline, Lidocaine Hydrochloride, Triamcinolone acetonide; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Drug Effect, Rib Fractures, Rib Trauma, Surgical Procedure, Unspecified, Pain; Catheter (Other), Nerve Pain, Local Infiltration, Anesthesia, Local, Intercostal Rib, Opioid Dependence, Chest Injury Trauma, Pneumonia
Interventions: Liposomal bupivacaine injection, Bupivacaine indwelling catheter; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Influenza
Interventions: GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 611 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more

Search by objective public record fields.

A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

Stellate Ganglion Blockade in Post-Menopausal Women

The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery

Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy

Safety, Tolerability, and Pharmacokinetics of CSX-1004

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Clofarabine Bone Marrow Cytoreduction

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris

Botulinum Toxin for the Management of Chronic Orchialgia

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Pharmacogenomics of GLP1 Receptor Agonists

Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine.

Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

Tranexamic Acid (TXA) in Hip Arthroscopy

A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty

TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone

Using Saline for Myofascial Pain Syndromes (USAMPS)

Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults